Max oncology inpatient revenue falls after chemotherapy drug discontinuation for CGHS patients
Speaking during the company’s second-quarter earnings call, Soi attributed the drop to revisions in CGHS rates.
We haven't written up this one. ETHealthworld has the full story — the link below goes straight to it.